个体化肿瘤知情循环肿瘤DNA检测在EV±P治疗晚期尿路上皮癌中的预后价值
这项多中心真实世界回顾性探索性分析纳入110例接受EV±P治疗的局部晚期或转移性尿路上皮癌患者,共545份血浆样本。基线ctDNA检出率93.6%,治疗中ctDNA阳性在各时间区间均与更差的无进展生存和总生存独立相关,12周内持续阳性预后更差,早期清除多见于影像学缓解者。
要点
- 治疗中ctDNA阳性与EV±P治疗患者更差的PFS和OS独立相关。
- 12周内ctDNA持续阳性者PFS和OS显著缩短。
- 早期ctDNA清除在影像学缓解者中更常见。
核心结论
- 个体化肿瘤知情ctDNA检测可提示EV±P治疗反应并预后生存获益。
研究设计与样本
- 探索性、真实世界、回顾性、多中心分析,纳入110例接受EV±P治疗的la/mUC患者,共545份血浆样本,中位随访60.6周。
主要发现
- 基线ctDNA检出率93.6%,12周内75.8%下降、33.9%清除。
- 治疗中ctDNA阳性与更差PFS相关:4-12周HR=10.08(p<0.001),12-24周HR=11.84(p<0.001),>24周HR=6.77(p<0.001)。
- 治疗中ctDNA阳性与更差OS相关:4-12周HR=6.53(p=0.013),12-24周HR=7.22(p=0.0083),>24周HR=3.81(p=0.025)。
- 12周内持续阳性与更短PFS(HR=8.96,p=0.0004)和OS(HR=4.58,p=0.016)相关。
- 早期ctDNA清除在影像学缓解者中更常见(p<0.001)。
临床怎么用
- 可考虑用连续ctDNA监测辅助判断EV±P治疗反应与预后风险。
局限性
- 回顾性设计。
- ctDNA采样未标准化。
- 评估和治疗方式存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Enfortumab vedotin (EV) plus pembrolizumab (P) is the preferred first-line therapy for locally advanced or metastatic urothelial carcinoma (la/mUC); however, responses remain heterogeneous, and biomarkers are limited. We evaluated longitudinal tumor-informed circulating tumor DNA (ctDNA) as a potential real-time prognostic biomarker in patients with la/mUC initiating EV with or without P (EV±P). DESIGN, SETTING AND PARTICIPANTS: This is an exploratory, real-world retrospective, multicenter analysis of patients with la/mUC who received personalized, tumor-informed ctDNA testing (Signatera, Natera, Inc.) coinciding with their EV±P treatment. RESULTS AND LIMITATIONS: Across 545 plasma samples from 110 patients (median follow-up 60.6 weeks (wk)), baseline ctDNA was detected in 93.6% and declined or cleared within 12 wk in 75.8% and 33.9%, respectively. In all evaluated time intervals, ctDNA positivity on-treatment was consistently associated with inferior progression-free survival (PFS) and overall survival (OS) compared to ctDNA negativity (PFS 4-12 wk: hazard ratio [HR] = 10.08; p < 0.001; 12-24 wk: HR = 11.84; p < 0.001; >24 wk: HR = 6.77; p < 0.001; OS 4-12 wk: HR = 6.53; p = 0.013; 12-24 wk: HR = 7.22; p = 0.0083; >24 wk: HR = 3.81; p = 0.025) and remained independently prognostic on multivariable analyses. ctDNA dynamics relative to baseline were similarly prognostic: persistent positivity within 12 wk was associated with shorter PFS (HR = 8.96; p = 0.0004) and OS (HR = 4.58; p = 0.016), whereas early ctDNA clearance was enriched among radiographic responders (p < 0.001). Limitations include the retrospective design, non-standardized ctDNA sample collection, and heterogeneity in evaluation and treatment approaches. CONCLUSIONS: Personalized, tumor-informed ctDNA testing can indicate response to EV±P and is prognostic of survival benefit in patients with la/mUC receiving EV±P.
引用
- Reyes KR, Zhu R, Herberts C, et al. Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab. Eur Urol Oncol. 2026. PMID: 42379901. doi:10.1016/j.euo.2026.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。